Volume 132, Issue 1, Pages 52-65 (January 2007) Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial  Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Robert Enns, Stephen B. Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D. Kent, Paul F. Pollack  Gastroenterology  Volume 132, Issue 1, Pages 52-65 (January 2007) DOI: 10.1053/j.gastro.2006.11.041 Copyright © 2007 AGA Institute Terms and Conditions

Figure 1 Trial profile. eow, every other week. Gastroenterology 2007 132, 52-65DOI: (10.1053/j.gastro.2006.11.041) Copyright © 2007 AGA Institute Terms and Conditions

Figure 2 (A) Clinical remission at weeks 26 and 56 in randomized responder population (week-4 responders). Remission defined as a decrease in CDAI score to <150. *P < .001 for pairwise comparison between each adalimumab treatment group and placebo. eow, every other week. (B) Clinical remission over time in randomized responder population (week-4 responders). P < .001 for adalimumab vs placebo at every time point at/after 6 weeks for 40 mg eow and at/after 12 weeks for 40 mg weekly. *P = .001 vs placebo; †P = .005 vs placebo. Gastroenterology 2007 132, 52-65DOI: (10.1053/j.gastro.2006.11.041) Copyright © 2007 AGA Institute Terms and Conditions

Figure 3 Mean (A) CDAI and (B) IBDQ total scores over time among week-4 responders. eow, every other week. Gastroenterology 2007 132, 52-65DOI: (10.1053/j.gastro.2006.11.041) Copyright © 2007 AGA Institute Terms and Conditions

Figure 4 Percentage of patients receiving corticosteroids at baseline who discontinued corticosteroid use and achieved clinical remission (randomized responder population) at weeks 26 and 56. Remission was defined as a decrease in CDAI score to <150. *P < .001; †P = .008. Gastroenterology 2007 132, 52-65DOI: (10.1053/j.gastro.2006.11.041) Copyright © 2007 AGA Institute Terms and Conditions

Figure 5 (A) Closure of draining fistulas (defined as closure of all fistulas draining at baseline for at least 2 consecutive visits) at weeks 26 and 56 during double-blind therapy in the randomized population of patients with draining fistulas at screening and baseline visits. Note that statistical analyses were not performed on individual adalimumab groups. *P = .043 for combined adalimumab groups versus placebo at week 26; P = .016 for combined adalimumab groups versus placebo at week 56. n, number of patients with fistulas at baseline; eow, every other week. (B) Patients with maintenance of healing of draining fistulas at weeks 26 and 56. *P = .043 for combined adalimumab groups versus placebo. Gastroenterology 2007 132, 52-65DOI: (10.1053/j.gastro.2006.11.041) Copyright © 2007 AGA Institute Terms and Conditions